Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Elementis FY operating profits grow, revenues slip

(Sharecast News) - Chemicals company Elementis revealed on Thursday that adjusted operating profits had ticked up in 2023 despite seeing a modest dip in revenues for the year. Elementis said adjusted operating profits were up 3% at $104.0m, with the company benefitting from pricing and cost reduction, as well as a material improvement in Talc profits. Adjusted operating margins improved from 13.6% to 14.6%.

However, revenue was down 3% to $713.0m A pricing and mix benefits were offset by lower volumes due to underlying demand weakness and destocking.

Net debt of $202.0m was 45% lower than the prior year, with the group boosted by proceeds from its sale of Chromium. Net debt to EBITDA reduced to 1.4x from 2.2x.

Elementis also said it had opted to reinstate its dividend, with a final dividend of 2.1 cents per share.

Looking forward, Elementis highlighted that it had made a "good start to the year", but noted the demand environment "remains uncertain". It also said it had a record new business pipeline of $363.0m, with 12 new products launched in the year.

Chief executive Paul Waterman said: "In 2023 Elementis delivered a resilient profit performance and an improved operating margin in the face of challenging market conditions.

"While market conditions remain uncertain, we believe that the combination of the growth and efficiency programmes will help us make material progress in 2024 against our 2026 financial targets."

As of 0900 GMT, Elementis shares were up 2.59% at 142.60p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Hikma boosts injectables business with Xellia assets acquisition
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.